MLMeghanne Lomibao

Meghanne Lomibao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Meghanne Lomibao has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Second- and Third-Line Outcomes after Selective RET Inhibitor Failure in RET Fusion-Positive Metastatic Lung Cancer: A Real-World Analysis from the RET-MAP Registry

    by Daniela Miliziano, Julia K. Rotow, Meghanne Lomibao, Arianna Marinello, Helena Bote-De Cabo, Fabrizio Citarella, Lorenza Landi, Massimiliano Cani, Mariana Brandão, Jamie Feng, et al.

    Purpose: Selective RET inhibitors (SRI) are the first-line standard for RET fusion–positive non–small cell lung cancer, but no treatment is established after progression. Real-world outcomes are needed to inform trial design and contextualize single-arm studies in this rare population. Experimental Design: Using the international RET-MAP registry (52 centers), we evaluated second-line platinum–pemetrexed (Pt-Pem) with or without immunotherapy (IO) after first-line SRI progression and characterized third-line treatments after exposure to both regimens in any order. Results: Among 207 patients treated with first-line SRI, 81 (39%) discontinued because of progression; 65 (80%) received subsequent therapy, most commonly Pt-Pem with or without IO (n = 35, 54%). At 53 months’ median follow-up, the real-world objective response rate was 41% (12/29), median real-world progression-free survival (rwPFS) was 6.1 months [95% confidence interval (CI), 4.8–11.4], and median overall survival (OS) was 13.7 months (95% CI, 8.7–26.5). Outcomes were similar with chemotherapy alone (n = 12) versus chemoimmunotherapy (n = 23) for rwPFS [5.9 vs. 6.8 months; hazard ratio (HR), 1.05; P = 0.903] and OS (18.5 vs. 13.7 months; HR, 0.83; P = 0.674). Three patients had rwPFS beyond 24 months with chemoimmunotherapy, all after short first-line SRI exposure. Among 32 patients receiving third-line therapy, taxane with or without antiangiogenic therapy was the most common (n = 11), with no responses and a median rwPFS of 1.5 months (95% CI, 0.8–NR). Conclusions: Second-line Pt-Pem with or without IO achieved a median rwPFS of 6.1 months. Third-line outcomes were poor, highlighting the need for new treatment strategies.

  • Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion–Positive Lung Cancers: A Phase II Trial of Cabozantinib

    by Jaime Rubio-Perez, Matteo Repetto, Ling Feng Ye, Rebecca Repetti, Clare Wilhelm, Jeeban P. Das, Christina Falcon, Meghanne Lomibao, Guilherme Harada, Mark G. Kris, et al.

    Purpose: All targeted therapies approved for ROS1 fusion–positive non–small cell lung cancer (NSCLC) are type I inhibitors. These tyrosine kinase inhibitors (TKI) may induce resistance amenable to type II inhibition. Cabozantinib is a type II ROS1/MET TKI with preclinical activity against on-target ROS1 resistance mutations and MET alterations. Patients and Methods: This single-center, open-label, phase II study (NCT01639508) enrolled patients with pretreated ROS1 fusion–positive NSCLC. The primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and safety. The first phase of the Simon two-stage design is reported. Results: Seven ROS1 TKI pretreated patients were enrolled. Previous treatment included crizotinib, entrectinib, repotrectinib, and zidesamtinib. The ORR was 43% [95% confidence interval (CI), 10%–81.5%]. The best response was −92% partial response (PR) in a patient with ROS1 D2033N–mutant cancer. Two additional PRs were achieved, one (−49%) in an ROS1 G2032R/L2086F–mutant cancer. The median PFS was 4.5 months [95% CI, 4–not estimable (NE)] with a median duration of response and OS of 8 (95% CI, 3–13) and 11 months (95% CI, 6–NE), respectively. Resistance mechanisms to cabozantinib were identified in two patients: MET overexpression and MET D1228N. The most frequent treatment-related toxicities observed were fatigue, nausea, and hypertension. Grade 3 treatment-related adverse events occurred in 57%, mostly palmar–plantar erythrodysesthesia (PPE) and transaminitis. All patients required a dose reduction. Conclusions: Cabozantinib achieved responses in pretreated ROS1 fusion–positive NSCLCs, even in the presence of multidrug-resistant mutations, highlighting the potential utility of type II ROS1 TKI therapy.

  • Open Access

    Supplementary Data1 from Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry

    by Arianna Marinello, Julia K. Rotow, Meghanne Lomibao, Daniela Miliziano, Rita Leporati, Jamie Feng, Giulio Metro, Mariana Brandão, Teresa Gorria, Amin H. Nassar, et al.

    Supplementary Tables and Figures.

  • Retreatment with First-Generation Selective RET Inhibitors in RET -Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry

    by Arianna Marinello, Julia K. Rotow, Meghanne Lomibao, Daniela Miliziano, Rita Leporati, Jamie Feng, Giulio Metro, Mariana Brandão, Teresa Gorria, Amin H. Nassar, et al.

    Purpose: In RET-rearranged non–small cell lung cancer (NSCLC), treatment options after first-generation selective RET inhibitors (SRI) are limited, and the value of SRI retreatment remains unclear. This study evaluates outcomes of SRI retreatment. Experimental Design: This multicenter retrospective study included patients with advanced RET-rearranged NSCLC who received ≥2 SRI-based therapy lines. Of 411 SRI-treated patients, 41 (10%) underwent SRI retreatment. Outcomes included objective response rate (ORR), progression-free survival (PFS), 6-month PFS, time to treatment failure, adverse events (AE). Results: Among 41 patients, 14 (34%) discontinued the initial SRI because of toxicity and 27 (66%) because of progression. After discontinuation for toxicity, all switched to an alternate SRI, achieving an ORR of 67%, median PFS of 9.9 months, and 6-month PFS of 80.3%. AEs reoccurred in nine patients (64%), with grade ≥3 AEs in 3 (21%) who switched at full dose. Among patients who discontinued because of progression, SRI monotherapy (n = 13) achieved an ORR of 23%, median PFS of 7 months, and 6-month PFS of 61.5%. Benefit was observed in patients with brain-only or oligoprogressive disease or dose reduction on first SRI. Combination therapy (n = 14; targeted agents, n = 11; chemotherapy, n = 3) achieved an ORR of 39%, median PFS of 4 months, and 6-month PFS of 27.3%. Conclusions: Same-class SRI switch after toxicity is feasible and clinically active but warrants cautious, dose-adjusted switching to mitigate toxicities. The efficacy of SRI rechallenge after progression seems limited overall. However, selected patients, such as those with brain-only or oligoprogressive disease, may derive benefit.

  • Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK -Rearranged Squamous and Adenosquamous Non–Small Cell Lung Cancers

    by Emily A. Miao, Beow Yeap, Sameh Daher, Meghanne Lomibao, Fangdi Sun, Rachel Keogh, Jason Lambden, Amanda Reyes, Jennifer L. Peterson, Joyce Liang, et al.

    PURPOSE: Anaplastic lymphoma kinase (ALK) is an established therapeutic target in non–small cell lung cancer (NSCLC), predominantly identified in adenocarcinomas. However, ALK rearrangements also occur in de novo squamous and adenosquamous NSCLCs and their clinicogenomic features remain poorly defined. METHODS: This multi-institutional retrospective analysis included patients with advanced ALK+ NSCLC. Patients with de novo ALK+ squamous and adenosquamous NSCLCs were identified and compared with an ALK+ adenocarcinoma cohort treated with first-line (1L) alectinib. Overall survival (OS), time to progression (TTP), and time to treatment discontinuation (TTD) were analyzed using the Kaplan-Meier methodology. RESULTS: Among 177 patients, 29 had ALK+ squamous (n = 17) and adenosquamous (n = 12) NSCLCs and 148 had ALK+ adenocarcinoma treated with 1L alectinib. Among patients receiving 1L alectinib, OS was significantly shorter for patients with adenosquamous (median, 31.0 months [95% CI, 17.0 to not reached {NR}]) and squamous (27.0 months [95% CI, 5.0 to 35.0]) tumors compared with that for patients with adenocarcinoma (median NR; median follow-up 51.2 months; P < .001). TTP was shorter for squamous (median, 8.0 months [95% CI, 2.0 to 12.0]) versus adenocarcinoma (median, 19.0 months [95% CI, 12.6 to 25.0]) cohorts ( P < .001), although the adenosquamous cohort had comparable TTP (median, 20.0 months [95% CI, 9.4 to 30.6]) with the adenocarcinoma cohort ( P = .70). TTD was significantly shorter for squamous (median, 9.5 months [95% CI, 1.5 to 13.0]) and adenosquamous (median, 20.0 months [95% CI, 3.0 to 24.0]) versus adenocarcinoma cohorts (52.3 months [95% CI, 40.5 to 57.5]; P < .001). Genomic profiling revealed more frequent TP53 (53% v 25%; P = .026), PDGFRA (16% v 0%; P = .009), KIT (11% v 0%; P = .045), PIK3CA (11% v 0%; P = .045), and MYC (11% v 0%; P = .045) coalterations in the squamous/adenosquamous cohort. CONCLUSION: ALK+ squamous and adenosquamous NSCLCs are rare, but biologically distinct, with inferior outcomes on 1L ALK TKI, highlighting the need for further research to develop effective treatment strategies.